Lexicon Pharmaceuticals LXRX Effective Income Tax Rate Reconciliation Tax Credits Research
Effective Income Tax Rate Reconciliation Tax Credits Research at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch.
The official record: Lexicon Pharmaceuticals’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's effective income tax rate reconciliation tax credits research.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's effective income tax rate reconciliation tax credits research?
- Lexicon Pharmaceuticals (LXRX) reported effective income tax rate reconciliation tax credits research of -1.9% in Q4 2025.
- What does effective income tax rate reconciliation tax credits research mean?
- The percentage reduction in the effective income tax rate attributable to research and development tax credits. It measures the effectiveness of R&D-related tax incentives in lowering the company's total tax liability.